Biogen Inc (BUE:BIIB)
ARS 18636 201.5 (1.09%) Market Cap: 28.98 Til Enterprise Value: 34.17 Til PE Ratio: 28.13 PB Ratio: 2.14 GF Score: 49/100

Biogen Inc at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 01:55PM GMT
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Pleased to have Biogen with me.

Before we get started, I just need to read a disclosure statement, and that is, please note that all important disclosures including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures or you can pick up a copy at the registration desk.

So I'm very pleased to have with me Jeff Capello, who's the CFO of Biogen. And Jeff, I thought I'd give you the opportunity to make some opening comments, and then we can jump into it.

Jeffrey D. Capello
Biogen Inc. - Executive VP & CFO

Great. Thank you, Matthew. Thank you to Morgan Stanley for having us at the conference this year, and we appreciate your interest in Biogen.

Before we start, I just want to share with you that I'm sure we'll get into

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot